Urogen Pharma Ltd (URGN)

$18.79 -0.46 (-2.39%)
Market Cap 890.58M
Revenue (ttm) 90.40M
Net Income (ttm) -126.87M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -140.34%
Debt to Equity Ratio -1.31
Volume 886,400
Avg Vol 1,201,134
Day's Range N/A - N/A
Shares Out 46.26M
Stochastic %K 18%
Beta 1.10
Analysts Strong Sell
Price Target $35.22

Company Profile

UroGen Pharma Ltd. engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; and Jelmyto for pyelocalyceal solution. The company's lead product candidate are UGN-102 for pyelocalyceal solution; UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution design...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
Gkon123
Gkon123 Sep. 10 at 7:21 PM
$URGN oh nice discount. back in boys
0 · Reply
ivocsev
ivocsev Sep. 10 at 7:07 PM
$URGN 10% drop for no reason?
0 · Reply
Richdenimjohnson
Richdenimjohnson Sep. 10 at 6:59 PM
$URGN we’re back a week later
0 · Reply
Dragonfire89
Dragonfire89 Sep. 10 at 6:55 PM
$URGN The good news is this 10% drop is on anemic volume. I bought more at 18.50 :)
0 · Reply
Jokei
Jokei Sep. 10 at 3:55 PM
$URGN bottom is in?
1 · Reply
A_Train1
A_Train1 Sep. 10 at 3:55 PM
$URGN really hoping this is just a stop loss raid…otherwise this is rough at 10%+ loss in 1 trading day…does someone know something?
1 · Reply
lukasgx
lukasgx Sep. 10 at 3:18 PM
$URGN from 21 to 18.80 in one trading day not expected at all !
0 · Reply
The_trader1
The_trader1 Sep. 10 at 3:16 PM
$URGN wtf??
0 · Reply
truehealthvalue
truehealthvalue Sep. 10 at 2:48 PM
$URGN adding
0 · Reply
A_Train1
A_Train1 Sep. 10 at 2:30 PM
$URGN what a bleed / such volatility
0 · Reply
Latest News on URGN
UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Sep 8, 2025, 8:00 AM EDT - 4 days ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Pharma to Present at Upcoming Investor Conferences

Aug 21, 2025, 8:00 AM EDT - 22 days ago

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma: Targeting Profits In 2027

Aug 18, 2025, 3:34 PM EDT - 25 days ago

UroGen Pharma: Targeting Profits In 2027

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

Aug 9, 2025, 3:05 AM EDT - 5 weeks ago

UroGen Pharma Ltd. (URGN) Q2 2025 Earnings Call Transcript

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 5 weeks ago

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Aug 5, 2025, 8:00 AM EDT - 5 weeks ago

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Jul 29, 2025, 8:00 AM EDT - 6 weeks ago

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

Jul 28, 2025, 8:00 AM EDT - 6 weeks ago

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 21, 2025, 8:00 AM EDT - 7 weeks ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 7, 2025, 8:00 AM EDT - 2 months ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

Jun 16, 2025, 8:17 AM EDT - 3 months ago

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 15, 2025, 10:17 AM EDT - 3 months ago

INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

UroGen Pharma: Lessons Learned And Future Outlook

Jun 13, 2025, 1:05 PM EDT - 3 months ago

UroGen Pharma: Lessons Learned And Future Outlook

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

Jun 12, 2025, 6:04 PM EDT - 3 months ago

SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of UroGen

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 12, 2025, 1:28 PM EDT - 3 months ago

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

US FDA approves Urogen's bladder cancer drug

Jun 12, 2025, 12:48 PM EDT - 3 months ago

US FDA approves Urogen's bladder cancer drug

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other  Cancer Subpopulation

Jun 10, 2025, 10:30 AM EDT - 3 months ago

UroGen: Despite ODAC Vote, Hope Remains With Targeting Of Other  Cancer Subpopulation

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

Jun 10, 2025, 8:47 AM EDT - 3 months ago

URGN LEGAL NOTICE: Lose Money when UroGen Pharma Ltd. Stock Plummeted 45%?

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

Jun 9, 2025, 1:36 PM EDT - 3 months ago

The Gross Law Firm Reminds Shareholders of a Lead Plaintiff Deadline of July 28, 2025 in UroGen Pharma Ltd. Lawsuit – URGN

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Jun 8, 2025, 8:18 AM EDT - 3 months ago

URGN INVESTOR NEWS: UroGen Pharma Ltd. has been Sued for Securities Fraud – Contact BFA Law before July 28 Deadline (NASDAQ:URGN)

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

Jun 5, 2025, 9:31 AM EDT - 3 months ago

Shareholders who lost money on UroGen Pharma Ltd. (NASDAQ: URGN) Should Contact Wolf Haldenstein

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

Jun 4, 2025, 3:46 PM EDT - 3 months ago

URGN LAWSUIT: UroGen Pharma Ltd. Lawsuit Alleges Securities Fraud Violations - Investors Notified to Contact BFA Law

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Jun 3, 2025, 3:33 PM EDT - 3 months ago

URGN STOCK NOTICE: UroGen Pharma Ltd. Has Been Sued for Fraud; Investors Are Notified to Contact BFA Law Before July 28 Legal Deadline

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Jun 3, 2025, 12:19 PM EDT - 3 months ago

Law Offices of Frank R. Cruz Encourages UroGen Pharma Ltd. (URGN) Investors To Inquire About Securities Fraud Class Action

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

Jun 3, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against UroGen Pharma Ltd. (URGN) And Encourages Shareholders to Reach Out

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Jun 2, 2025, 11:00 AM EDT - 3 months ago

UroGen Presents uTRACT Registry at ASCO 2025 Annual Meeting Designed to Study Real-World Use of JELMYTO in Low-Grade Upper Tract Urothelial Cancer

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

Jun 2, 2025, 10:00 AM EDT - 3 months ago

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against UroGen Pharma Ltd. (URGN) and Encourages Shareholders to Learn More About the Investigation

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 2, 2025, 10:00 AM EDT - 3 months ago

UroGen Announces Data at ASCO 2025 Annual Meeting on UGN-102, an Investigational Treatment for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Jun 1, 2025, 10:00 AM EDT - 3 months ago

UroGen Pharma Ltd. (URGN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation

Gkon123
Gkon123 Sep. 10 at 7:21 PM
$URGN oh nice discount. back in boys
0 · Reply
ivocsev
ivocsev Sep. 10 at 7:07 PM
$URGN 10% drop for no reason?
0 · Reply
Richdenimjohnson
Richdenimjohnson Sep. 10 at 6:59 PM
$URGN we’re back a week later
0 · Reply
Dragonfire89
Dragonfire89 Sep. 10 at 6:55 PM
$URGN The good news is this 10% drop is on anemic volume. I bought more at 18.50 :)
0 · Reply
Jokei
Jokei Sep. 10 at 3:55 PM
$URGN bottom is in?
1 · Reply
A_Train1
A_Train1 Sep. 10 at 3:55 PM
$URGN really hoping this is just a stop loss raid…otherwise this is rough at 10%+ loss in 1 trading day…does someone know something?
1 · Reply
lukasgx
lukasgx Sep. 10 at 3:18 PM
$URGN from 21 to 18.80 in one trading day not expected at all !
0 · Reply
The_trader1
The_trader1 Sep. 10 at 3:16 PM
$URGN wtf??
0 · Reply
truehealthvalue
truehealthvalue Sep. 10 at 2:48 PM
$URGN adding
0 · Reply
A_Train1
A_Train1 Sep. 10 at 2:30 PM
$URGN what a bleed / such volatility
0 · Reply
Jokei
Jokei Sep. 9 at 5:26 PM
$URGN wake up
0 · Reply
G101SPM
G101SPM Sep. 9 at 3:08 PM
G101SPM 8/19/2025, 8:02:32 AM $URGN $19.65 bid. DAC (dollar average cost includes partial SELLS at a profit to reduce net cost to zero). CHANGE EXIT TO $35.00 FROM $18.00 on improved SPM tag.
0 · Reply
Main_Street_Risks
Main_Street_Risks Sep. 9 at 2:02 AM
$URGN I thought this was going to bleed after approval. I sold way too early. The pa makes me wonder if someone is going to scoop them up. Even from the sidelines I love to see this. Good luck to longs. Godspeed to the company.
2 · Reply
ap20
ap20 Sep. 8 at 9:47 PM
$URGN Somebody cranked this thing up today..
1 · Reply
deweyeggbert
deweyeggbert Sep. 8 at 7:32 PM
$URGN calls are getting warm. Glad I bought a ton of em.
0 · Reply
Black_bull
Black_bull Sep. 8 at 7:21 PM
$URGN https://www.globenewswire.com/news-release/2025/09/08/3146045/0/en/UroGen-Pharma-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html Inducement of grants to 40 new employees
0 · Reply
Jokei
Jokei Sep. 8 at 7:08 PM
$URGN time to break out of 52 week high
0 · Reply
JFDI
JFDI Sep. 8 at 6:57 PM
YOOOOOO!!!! The situation is $URGN
0 · Reply
CoffeeMaestro
CoffeeMaestro Sep. 8 at 3:58 PM
$URGN Sufficient Cash left to fund operations through profitability
0 · Reply
Richdenimjohnson
Richdenimjohnson Sep. 8 at 3:29 PM
$URGN any news?
1 · Reply
ripztrip
ripztrip Sep. 7 at 2:45 PM
$CAPR Bottom line summary $PGEN $URGN $SRPT
1 · Reply
Stormfury66
Stormfury66 Sep. 5 at 6:18 PM
$CAPR $PGEN $SRPT $URGN It’s 30% abv the past month volume & steadily rising expect big spike in volume next
0 · Reply